Rothschild Capital Partners LLC acquired a new position in GW Pharmaceuticals PLC- (NASDAQ:GWPH) during the second quarter, Holdings Channel reports. The firm acquired 3,000 shares of the biopharmaceutical company’s stock, valued at approximately $275,000.

A number of other institutional investors also recently bought and sold shares of the company. Geode Capital Management LLC raised its position in GW Pharmaceuticals PLC- by 2.4% in the first quarter. Geode Capital Management LLC now owns 6,072 shares of the biopharmaceutical company’s stock worth $438,000 after buying an additional 141 shares during the period. Ladenburg Thalmann Financial Services Inc. raised its position in GW Pharmaceuticals PLC- by 12.3% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,960 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 214 shares during the period. IFP Advisors Inc raised its position in GW Pharmaceuticals PLC- by 15.3% in the first quarter. IFP Advisors Inc now owns 1,759 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 234 shares during the period. Seven Eight Capital LLC raised its position in GW Pharmaceuticals PLC- by 216.7% in the first quarter. Seven Eight Capital LLC now owns 1,900 shares of the biopharmaceutical company’s stock worth $137,000 after buying an additional 1,300 shares during the period. Finally, Rothschild Investment Corp IL bought a new position in GW Pharmaceuticals PLC- during the second quarter worth approximately $200,000.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) traded up 2.73% during midday trading on Tuesday, hitting $108.29. The company had a trading volume of 826,360 shares. The firm’s 50 day moving average is $90.97 and its 200-day moving average is $84.99. GW Pharmaceuticals PLC- has a 52 week low of $35.83 and a 52 week high of $111.82. The firm’s market capitalization is $2.37 billion.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last posted its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($1.21) by $1.15. The firm earned $3.10 million during the quarter, compared to analysts’ expectations of $3.63 million. During the same quarter in the previous year, the company posted ($0.09) EPS. GW Pharmaceuticals PLC-‘s revenue for the quarter was down 73.3% on a year-over-year basis. On average, equities research analysts expect that GW Pharmaceuticals PLC- will post ($4.52) EPS for the current fiscal year.

A number of equities analysts have commented on the company. Piper Jaffray Cos. restated a “buy” rating and set a $147.00 price objective on shares of GW Pharmaceuticals PLC- in a research note on Sunday, June 26th. Leerink Swann raised their price objective on GW Pharmaceuticals PLC- to $138.00 and gave the stock a “buy” rating in a research note on Monday, June 27th. Vetr upgraded GW Pharmaceuticals PLC- from a “buy” rating to a “strong-buy” rating and set a $91.16 price objective on the stock in a research note on Wednesday, August 17th. Janney Montgomery Scott assumed coverage on GW Pharmaceuticals PLC- in a research note on Monday, June 27th. They set a “sell” rating and a $40.00 price objective on the stock. Finally, Cowen and Company reaffirmed a “buy” rating and issued a $135.00 target price on shares of GW Pharmaceuticals PLC- in a report on Monday, June 27th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $126.01.

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc is involved in the development of cannabinoid prescription medicines using botanical extracts derived from the Cannabis Sativa plant. The Company develops a portfolio of cannabinoid medicines, including Epidiolex, which is an oral medicine for the treatment of refractory childhood epilepsies.

5 Day Chart for NASDAQ:GWPH

Want to see what other hedge funds are holding GWPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GW Pharmaceuticals PLC- (NASDAQ:GWPH).

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with Analyst Ratings Network's FREE daily email newsletter.